公开(公告)号：WO2005047511A3

公开(公告)日：2005-11-24

申请号：PCT/US2004036981

申请日：2004-11-06

Applicant: GENENCOR INT ,  ESTELL DAVID A ,  POWER SCOTT D ,  COLLIER KATHERINE D ,  DE NOBEL HANS ,  GANSHAW GRANT C ,  KOLKMAN MARC ,  MILLER JEFF ,  SCHMIDT BRIAN ,  VAN KIMMENADE ANITA ,  VOGTENTANZ GUDRUN

Inventor： ESTELL DAVID A ,  POWER SCOTT D ,  COLLIER KATHERINE D ,  DE NOBEL HANS ,  GANSHAW GRANT C ,  KOLKMAN MARC ,  MILLER JEFF ,  SCHMIDT BRIAN ,  VAN KIMMENADE ANITA ,  VOGTENTANZ GUDRUN

IPC: A61K38/08 ,  A61K38/54 ,  A61K38/55 ,  C07H21/04 ,  C07K7/06 ,  C07K14/81 ,  C12N1/21 ,  C12N9/99 ,  C12N15/62 ,  C12N15/74 ,  C12P21/06

CPC classification number: C07K14/81 ,  A61K38/00 ,  C07K7/06 ,  C07K14/811 ,  C07K2319/00 ,  C12N15/62

Abstract: The present invention provides compositions and methods related to expression of protease inhibitors and variants thereof in bacterial species. The present invention further provides fusion nucleic acids, vectors, fusion polypeptides, and processes for obtaining the protease inhibitors.

Abstract translation: 本发明提供了与在细菌物种中表达蛋白酶抑制剂及其变体有关的组合物和方法。 本发明进一步提供融合核酸，载体，融合多肽和获得蛋白酶抑制剂的方法。

公开(公告)号：WO2005074381A2

公开(公告)日：2005-08-18

申请号：PCT/IL2005/000016

申请日：2005-01-04

Applicant: RAMBAM MEDICAL CENTER, FUNDS FOR MEDICAL RESEARCH DEVELOPMENT OF INFRASTRUCTURE AND HEALTH SERVICES ,  LARISCH, Sarit ,  GOTTFRIED, Yossi

Inventor： LARISCH, Sarit ,  GOTTFRIED, Yossi

IPC: A61K38/54 ,  C12Q1/68 ,  G01N33/50 ,  G01N33/574 ,  G01N33/68

CPC classification number: G01N33/6845 ,  G01N33/5011 ,  G01N33/6803 ,  G01N2500/00 ,  G01N2510/00

Abstract: The present invention provides complexes containing an ARTS protein and an IAP protein, compounds that disrupt same, and use of the compounds in treating neuro-degenerative disease, ischemic injury, myelodysplasia, atherosclerosis, various auto-immune diseases, cytopenia, pancreatitis, and periodonitis, and in decreasing susceptibility of a cell to apoptosis. The present invention also provides methods for identifying biologically active regions of ARTS protein, and use of mimetic compounds of same in treating apoptosis-related disorders, cancer, and other neoplastic diseases and disorders.

Abstract translation: 本发明提供了含有ARTS蛋白质和IAP蛋白质的复合物，其破坏的化合物，以及该化合物在治疗神经退行性疾病，缺血性损伤，骨髓增生异常，动脉粥样硬化，各种自身免疫疾病，血细胞减少，胰腺炎和牙周炎中的用途 ，并降低细胞凋亡的易感性。 本发明还提供用于鉴定ARTS蛋白质的生物活性区域的方法，以及使用其模拟化合物治疗凋亡相关病症，癌症和其它肿瘤性疾病和病症的方法。

公开(公告)号：WO2004030693A1

公开(公告)日：2004-04-15

申请号：PCT/IT2002/000624

申请日：2002-10-01

Applicant: AMMANNATI, Paola ,  GIORDANI, Roberto

Inventor： AMMANNATI, Paola ,  GIORDANI, Roberto

IPC: A61K38/54

CPC classification number: A61K38/44 ,  A61K38/443 ,  A61K38/4813 ,  C12Y101/01021 ,  C12Y101/01049 ,  C12Y111/01009 ,  C12Y304/13009 ,  A61K2300/00

Abstract: A kit for the treatment of retinitis pigmentosa containing the enzymes glutathione peroxidase, prolidase, glucose-6-phosphate dehydrogenase and, optionally, aldose reductase in aliquot parts and interactive quantities appropriate for administering said enzymes in accordance with a predetermined time sequence.

Abstract translation: 一种用于治疗含有酶谷胱甘肽过氧化物酶，唾液酸酶，葡萄糖-6-磷酸脱氢酶和任选地，等分试样部分中的醛糖还原酶和适于根据预定时间顺序施用所述酶的相互作用量的视网膜色素变性的试剂盒。

公开(公告)号：WO03086178A2

公开(公告)日：2003-10-23

申请号：PCT/US0311265

申请日：2003-04-11

Applicant: CHILDRENS MEDICAL CENTER ,  SOKER SHAY ,  SATCHI-FAINARO RONIT

Inventor： SOKER SHAY ,  SATCHI-FAINARO RONIT

IPC: A61B20060101 ,  A61K38/00 ,  A61K38/17 ,  A61K38/54 ,  A61K49/00 ,  A61B

CPC classification number: A61K38/1709 ,  A61K38/1816 ,  A61K38/39 ,  A61K38/484 ,  A61K47/58 ,  G01N33/5064

Abstract: The present invention relates to methods for decreasing or inhibiting disorders associated with vascular hyperpermeability and to methods of screening for compounds that affect permeability, angiogenesis and stabilize tight junctions. In one aspect of the present invention there is provided a method of decreasing or inhibiting vascular hyperpermeability in an individual in need of such treatment. The method includes administering to the individual an effective amount of an antiangiogenic compound selected from the group consisting of endostatin, thrombospondin, angiostatin, tumstatin, arrestin, recombinant EPO and polymer conjugated TNP-470. Other antiangiogenic compounds are disclosed herein.

Abstract translation: 本发明涉及减少或抑制与血管高渗透性相关的疾病的方法以及筛选影响通透性，血管发生和稳定紧密连接的化合物的方法。 在本发明的一个方面，提供了减少或抑制需要这种治疗的个体血管高渗透性的方法。 该方法包括向个体施用有效量的选自由内皮抑制素，血小板反应素，血管抑素，肿瘤抑素，抑制蛋白，重组EPO和聚合物共轭TNP-470组成的组的抗血管生成化合物。 本文公开了其它抗血管生成化合物。

公开(公告)号：WO02043755A1

公开(公告)日：2002-06-06

申请号：PCT/EP2001/013897

申请日：2001-11-28

IPC: A61K38/54 ,  A61K36/00 ,  A61K36/18 ,  A61K36/88 ,  A61K38/46 ,  A61K38/48 ,  A61P17/02 ,  A61P17/06 ,  A61P19/02 ,  A61P29/00 ,  A61P37/00 ,  A61P37/08 ,  A61K35/78

CPC classification number: A61K36/88 ,  A61K38/4873 ,  A61K2300/00

Abstract: The present application pertains to the use of bromelain preparing a medicament for increasing the IL-(8) level in an individual so as to reduce or prevent inflammation in said individual and as an adjuvant therapy during wound healing processes.

Abstract translation: 本申请涉及使用制备用于增加个体中的IL（8）水平的药物的菠萝蛋白酶，以减少或预防所述个体的炎症，并且在伤口愈合过程中作为辅助治疗。

公开(公告)号：WO01094616A1

公开(公告)日：2001-12-13

申请号：PCT/US2001/017751

申请日：2001-06-01

IPC: C12N15/09 ,  A61K38/52 ,  A61K45/00 ,  A61P3/06 ,  A61P9/10 ,  A61P43/00 ,  C12Q1/02 ,  C12Q1/48 ,  C12Q1/52 ,  C12Q1/533 ,  C12Q1/00 ,  A61K38/00 ,  A61K38/51 ,  A61K38/54 ,  C07H21/04 ,  C07K1/00 ,  C07K16/00 ,  C12Q1/26 ,  C12Q1/30 ,  C12Q1/32 ,  C12Q1/34 ,  C12Q1/37 ,  C12Q1/40 ,  C12Q1/42 ,  C12Q1/44 ,  C12Q1/46 ,  C12Q1/50 ,  C12Q1/58 ,  C12Q1/60

CPC classification number: C12Q1/52 ,  A61K38/52 ,  C12Q1/533

Abstract: Protein markers of toxicity and efficacy for drugs are determined. For example, methods and reagents are disclosed for determining whether a patient receiving an antilipemic drug, especially a statin or HMGCoA reductase inhibiting drug, is experiencing drug efficacy and/or toxicity. Individual susceptibility is also determined prior to treatment. Also, drug discovery of similar acting candidates and their likelihood of being toxic or effective is determined by analysis of all proteins in a sample simultaneously by 2-dimensional gel elecrotphoresis.

Abstract translation: 确定药物的毒性和功效的蛋白质标记。 例如，公开了用于确定接受抗脂药物，特别是他汀类药物或HMGCoA还原酶抑制药物的患者是否正在经历药物功效和/或毒性的方法和试剂。 个体易感性也在治疗前确定。 此外，通过用二维凝胶电泳法同时分析样品中的所有蛋白质来确定类似作用候选物的药物发现及其有毒或有效的可能性。

公开(公告)号：WO0124816A3

公开(公告)日：2001-10-11

申请号：PCT/US0026627

申请日：2000-09-27

Applicant: KLAIRE LAB INC ,  WILKINSON RANDALL EUGENE ,  HOUSTON DEVIN B

Inventor： WILKINSON RANDALL EUGENE ,  HOUSTON DEVIN B

IPC: A23L1/305 ,  A61K38/43 ,  A61K38/54 ,  A61P25/00 ,  A61K38/48 ,  A23L1/30

CPC classification number: A61K38/44 ,  A23L33/17 ,  A61K38/4813 ,  C12Y114/16001 ,  C12Y114/18001 ,  C12Y304/14005 ,  A61K2300/00

Abstract: Compositions and methods able to reduce opioid-related symptoms in a human patient of an exorphin selected from the group consisting of a gluteomorphin and a caseomorphin, comprising a physiologically effective amount of a purified casomorphin inhibitor selected from the group consisting of a casomorphinase and a casomorphin ligand, a physiologically effective amount of a purified gluteomorphin inhibitor selected from the group consisting of a gluteomorphinase and a gluteomorphin ligand, and at least one of the group consisting of a physiologically acceptable carrier, adjuvant, excipient, buffer and diluent. In some embodiments, the compositions and methods further comprise a physiologically effective amount of an enkephalin inhibitor, preferably an enkephalinase, and a physiologically effective amount of an endorphin inhibitor, preferably an endorphinase.

Abstract translation: 能够减少选自下组的exorphin中的阿片样物质相关症状的组合物和方法，该组合物包含生理有效量的选自下组的胱天蛋白酶抑制剂和casomorphin 配体，生理学上有效量的选自糠醛吗啡酶和gl肌配体的纯化gl肌抑制剂，以及由生理上可接受的载体，佐剂，赋形剂，缓冲液和稀释剂组成的组中的至少一种。 在一些实施方案中，组合物和方法还包含生理有效量的脑啡肽抑制剂，优选脑啡肽酶和生理有效量的内啡肽抑制剂，优选内啡肽。

公开(公告)号：WO00054799A3

公开(公告)日：2001-04-26

申请号：PCT/EP2000/002261

申请日：2000-03-15

IPC: C12N9/14 ,  A61K38/43 ,  A61K38/46 ,  A61K38/47 ,  A61K38/54 ,  A61P3/10

CPC classification number: A61K38/465 ,  A61K38/47 ,  A61K38/48 ,  A61K2300/00

Abstract: The invention relates to the use of physiologically acceptable enzyme mixtures with lipolytic, proteolytic and amylolytic activity, of microbial or animal origin, but especially to the use of digestive enzyme mixtures such as pancreatin or digestive enzyme mixtures containing pancreatin, for treating diabetes. The invention also relates to the production of medicaments suitable for this treatment. One variant of the invention relates to the use of this enzyme mixture with lipolytic, proteolytic and amylolytic activity, especially digestive enzyme mixtures such as pancreatin or digestive enzyme mixtures containing pancreatin, for the adjuvant treatment of Type I and Type II Diabetes mellitus.

Abstract translation: 描述使用具有微生物或动物来源的脂解，蛋白水解和淀粉分解活性生理上可接受的酶混合物，但特别是消化酶混合物如例如的 胰酶或消化酶混合物对糖尿病的治疗含胰酶的，和用于制备适于这种治疗的药物。 在一个变型中，本发明涉及具有脂解，蛋白水解和淀粉分解活性使用这种酶混合物，但特别的胰酶或含胰酶的消化酶混合物用于辅助治疗糖尿病的I型和II型。

公开(公告)号：WO00059533A1

公开(公告)日：2000-10-12

申请号：PCT/US2000/007981

申请日：2000-03-24

IPC: A61K38/46 ,  A61K38/43 ,  A61K38/54 ,  C12N9/82

CPC classification number: A61K38/50 ,  C12Y305/01001 ,  C12Y305/01002 ,  Y02A50/473

Abstract: Described herein are methods for using asparaginases and/or glutaminases to treat patients with asparagine and/or glutamine-dependent diseases. Some diseases specifically envisioned to be treated by the methods of the invention include Graft versus Host disease and auto-immune diseases, including SLE, RA, diabetes, and AIDS. The glutaminases and asparaginases can be native or recombinant, and can be modified by acylation or pegylation, for example.

Abstract translation: 本文描述了使用天冬酰胺酶和/或谷氨酰胺酶治疗天冬酰胺和/或谷氨酰胺依赖性疾病的患者的方法。 一些专门设想用本发明方法治疗的疾病包括移植物抗宿主病和自身免疫疾病，包括SLE，RA，糖尿病和AIDS。 谷氨酰胺酶和天冬酰胺酶可以是天然的或重组的，并且可以通过酰化或聚乙二醇化进行修饰。

公开(公告)号：WO00021547A3

公开(公告)日：2000-09-08

申请号：PCT/EP1999/007634

申请日：1999-10-12

IPC: A61K31/7048 ,  A61K38/00 ,  A61K38/48 ,  A61K38/54 ,  A61P37/00 ,  A61P37/06

CPC classification number: A61K38/4826 ,  A61K38/4873 ,  A61K38/57 ,  A61K45/06 ,  C12Y304/21004 ,  C12Y304/22002 ,  C12Y304/22033 ,  A61K2300/00

Abstract: The invention relates to the utilization of at least one proteolytic enzyme to influence hyperactive T cells. Preferred proteolytic enzymes are trypsin, bromelain and papain. Rutin can additionally be utilized.

Abstract translation: 本发明涉及至少一种蛋白水解酶用于影响活动过度的T细胞的用途。 优选的蛋白水解酶是胰蛋白酶，菠萝蛋白酶和木瓜蛋白酶。 另外，可以使用芸香苷。